N/A
N=300
The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade
Residual Neuromuscular Blockade in Elderly Patients
Bottom Line
View on ClinicalTrials.gov: NCT01545193 ↗Enrolled (actual)
300
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcome: Primary: Incidence of Residual Neuromuscular Blockade — 45; 86 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Age and incidence of residual neuromuscular blockade (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Endeavor Health
- Primary completion
- Sep 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Residual Neuromuscular Blockade |
45; 86 | — |
| SECONDARY Signs and Symptoms of Residual Neuromuscular Blockade |
2; 4 | — |
| SECONDARY Respiratory Events Potentially Related to Residual Neuromuscular Blockade |
26; 57 | — |
| SECONDARY PACU Length of Stay |
73; 92 | — |
Summary
Residual neuromuscular blockade is frequently observed in the early postoperative period when patients have received a general anesthetic with muscle relaxants. At the present time it is uncertain whether certain patient populations are at greater risk for this common anesthetic complication. However, it is possible that elderly surgical patients may exhibit a higher incidence of residual neuromuscular blockade. The aim of this clinical trial is to determine the incidence of residual neuromuscular blockade in a cohort of younger (ages 18-50) and older (ages 70-90) patients undergoing surgery and general anesthesia.
Eligibility Criteria
Inclusion Criteria
- Patients presenting for elective surgical procedures with an expected duration greater than 45 minutes.
- ASA I to III patients ≥ 18 years of age, presenting for surgery requiring maintenance of neuromuscular blockade in the operating room, will be eligible for enrollment.
Exclusion Criteria
- presence of an underlying neuromuscular disease
- use of drugs known to interfere with neuromuscular transmission (antiseizure medications, anticholinesterases, magnesium sulfate)
- renal insufficiency (serum creatinine > 1.8 mg/dL) or renal failure.
Data sourced from ClinicalTrials.gov (NCT01545193). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.